Technological Update27 Sep 2018 08:21
ADVANCED ONCOTHERAPY PLC
(“Advanced Oncotherapy” or the “Company”)
Technological update
Key technological milestone completed on schedule
LIGHT system now generating proton beams with energies required to treat superficial tumours
Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, provides an update on the technological development of its LIGHT system.
The Company announces that it has reached a key milestone in the development of its next-generation proton therapy technology, the LIGHT system. The first system under development at the Company’s testing facility at CERN, Geneva is now generating a proton beam with sufficient energy required for treating some superficial tumours.
Superficial tumours include ocular tumours, parotid gland tumours, basal cell carcinoma, and some soft tissue sarcomas, to name a few. A specific type of basal cell carcinoma, known as periocular tumours, was modelled for the purpose of establishing the treatment plan based on the data and the proton acceleration reached with the LIGHT system. Periocular tumours are challenging to treat because of their proximity to the eye. Protons may offer an advantage for these patients by largely sparing the eyes and eye lenses from radiation dose.
The resulting plan is available on the website of the company and ‑ based on the proton acceleration generated ‑ shows that:
· The current LIGHT system comfortably covers the simulated clinical case, as well as some marginally deeper tumours
· The healthy tissue ‑ such as the eye and the lens ‑ is dramatically spared from radiation dose with a steep decrease of the radiation levels directly next to the tumour site
· The lens dose is well controlled and the radiation dose around the optic nerve is near zero
The Treatment Planning Software (“TPS”) used in the LIGHT system has been developed by AVO’s partner, RaySearch AB and will be further tailored to include LIGHT system’s many advanced features for AVO’s proprietary use.
The LIGHT system is designed to elicit significant advantages over existing proton therapy technology, such as a higher beam precision and targeting which results in a more conformal dose and greater adjustability at source. Furthermore, the accelerator varies the beam energy actively and therefore significantly reduces undesired secondary radiation seen in traditional proton therapy systems. This ‑ together with the modular design of the LIGHT system ‑ result in thinner radiation shielding next to the accelerator and a smaller foot-print. This makes the LIGHT systems easier and cheaper to operate and install in city-centre locations as compared to systems currently on the market. Taken altogether, these features make the LIGHT system the ideal tool for making proton therapy systems more widely available, with a technology expected to be capable of providing improved outcomes and reduced treatment related
Sign In
Follow the stocks
